US/UK/Canada

Share

Contacts

  • Göran Beijer

    • Links

    Pick a time period -
    Tags ( Active)

    All participants in Dicot Pharma's phase 2a study are dosed

    Uppsala, Sweden, June 25, 2025. Today, the potency drug developer Dicot Pharma announces that the enrolment in the ongoing phase 2a study has been completed and that all participants have been dosed. Hence, the company can now conclude that the clinical study will be completed in August. The results will be reported no later than three months thereafter.Dicot Pharma's clinical phase 2a study is fully enrolled and all participants have also been dosed. The company has previously communicated that the study is expected to be completed by mid-2025. As the last participant has now been dosed,

    Dicot Pharma’s new findings on mechanism of action: "affects the nerves controlling penile erection"

    Uppsala, Sweden, May 28, 2025. Dicot Pharma can today announce that the latest studies on the mechanism of action of their candidate drug LIB-01 show that it affects nerves and vascular structures which interact in creating penile erection. The results can also explain LIB-01's long-lasting effect and emphasize the differentiation to current potency drugs.Dicot Pharma has previously announced that the mechanism of action of the drug candidate LIB-01 differs from currently used potency drugs and thus has the potential to change the paradigm of erectile dysfunction management. The company is

    Report from the Annual General Meeting of Dicot Pharma

    Uppsala, Sweden, May 6, 2026. Dicot Pharma AB held its Annual General Meeting today in Uppsala where the following decisions were made.Annual report and results The meeting adopted the income statements and balance sheets according to the accounting documents presented and decided in accordance with the Board's proposal that the profit for the year be carried forward. No dividend will be paid. Discharge from liability The Meeting discharged the members of the Board of Directors and the Managing Director from liability for the management of the company's affairs during the financial

    Dicot Pharma presents interim report Q1 2025

    Uppsala, Sweden, April 29, 2025. Dicot Pharma AB publishes its interim report for the first quarter of 2025. The report is available as an attached document and on www.dicotpharma.com. The company's CEO Elin Trampe and CFO Björn Petersson will present the report in a webcast, sub-titled in English, at 10.00 CET, a broadcast that can also be viewed afterwards - see link below.First quarter, January-March 2025 · Net sales amounted to SEK 0.0 (0.0) million · Earnings after financial items amounted to SEK -22.9 (-13.6) million · Earnings per share amounted to SEK -0.01 (-0.02) “A

    Dicot Pharma publishes its annual report for 2024

    Uppsala, Sweden, April 17, 2025. Today, the pharmaceutical company Dicot Pharma AB publishes the English version of its annual report for 2024.For Dicot Pharma, 2024 was characterized by strong progress and significant study results where several important development milestones were passed. An oversubscribed rights issue has resulted in a good financial situation. The company notes that interest from both investors and medical experts is increasing. The full annual report in English is available at www.dicotpharma.com/investor-relations/.

    Summon to Annual General Meeting in Dicot Pharma May 6 at 17.00

    Uppsala, Sweden, April 3, 2025. The shareholders of Dicot Pharma AB, (reg. no. 559006-3490), are hereby invited to the Annual General Meeting to be held on Tuesday May 6, 2025, at 17.00 at Advokatfirman Lindahl at Vaksalagatan 10, Uppsala. Sandwiches, coffee and drinks will be served from 16.30.The meeting is open for shareholders. Information on how to register, the agenda, and a description of proposals is available at www.dicotpharma.com. This is a short summary in English, for the full summon in Swedish please refer to the website.   Uppsala in April, 2025 Dicot Pharma AB

    Dicot Pharma’s TO 6 subscribed at 96% and provides the company SEK 43.8 million

    Uppsala, Sweden, April 2, 2025. The exercise of warrants series TO 6 in Dicot Pharma was approximately 95.95 percent. Through the exercise of 115,281,330 warrants, 230,562,660 shares were subscribed for at a price of SEK 0.19 per share. Dicot Pharma will thus receive approximately SEK 43.8 million before issue costs. No subscription guarantees had been procured." A 96% subscription rate is a very good result in the current market and we feel great appreciation for everyone who participated and subscribed. I understand that with this we have received the second largest proceeds from an

    Last day of trading in Dicot Pharma TO 6 warrants tomorrow, March 27

    Uppsala, Sweden, March 26, 2025. The last day of trading in warrants TO 6 in Dicot Pharma is tomorrow, March 27, 2025. Warrant holders who cannot or do not intend to exercise their warrants are therefore encouraged to sell them no later than tomorrow so that other investors have the opportunity to exercise them. Tomorrow is therefore also the last day to buy more TO 6.Buying and selling TO 6 Until tomorrow, March 27, it is possible to trade in "DICOT TO 6" through nominees such as Avanza, Nordnet, or other banks. Trading means that holders who cannot or do not intend to exercise the

    Dicot Pharma invites to a Q&A session on TO 6

    Uppsala, March 17, 2025. Dicot Pharma invites to a Q&A session regarding the ongoing exercise of warrants in TO 6. The Q&A session will take place via Zoom on March 20 at 12.30. The session will be held in Swedish.Dicot Pharma's warrants of series TO 6 have a redemption period and can be exercised March 17-31. To answer any questions, a Q&A session in Swedish will take place via Zoom on Thursday, March 20 at 12.30 and will also be available for viewing afterwards. Questions can be asked online at the session or before via info@dicotpharma.com.   CEO Elin Trampe comments: "We want to

    Exercise Period for Warrants TO6 in Dicot Pharma Begins Today

    Uppsala, Sweden, March 17, 2025. The exercise period for the warrants of series TO6, which were issued in connection with Dicot Pharma’s rights issue of units in August 2024, begins today. The exercise period runs until March 31, 2025.Each warrant of series TO6 entitles the holder to subscribe for two new shares during the period March 17-31, 2025, at the subscription price of SEK 0.38 per warrant, equivalent to SEK 0.19 per share. If all warrants are exercised, Dicot Pharma will receive approximately SEK 45.7 million before costs.   To prevent the warrants from expiring worthless,

    Letters of Intent from Major Shareholders, Board, and Management to Subscribe for SEK 11 million in Dicot Pharma’s TO 6, Running Until March 31, 2025

    Uppsala, Sweden, March 13, 2025. Major shareholders in Dicot Pharma and all members of the board and management holding warrants of series TO 6 have declared their intention to exercise them. This corresponds to a total investment of approximately SEK 11 million, or about 24 percent of the total outstanding warrants. The subscription period for TO 6 runs March 17 until March 31, 2025.“It is very pleasing that we are once again seeing strong support from our major shareholders, board and management. This confidence means a lot and it feels extra valuable to be able to announce this even

    Subscription Price SEK 0.38 for Warrants TO 6 in Dicot Pharma Determined; corresponding to SEK 0.19 per share

    Uppsala, Sweden, March 11, 2025. Dicot Pharma carried out a rights issue of units in August 2024 where all those who were allocated shares also received warrants in series TO 6. Each warrant now entitles to subscribe for two new shares during the period March 17-31, 2025. The subscription price has been determined at SEK 0.38 per warrant or SEK 0.19 per share. This corresponds to 70% of the volume-weighted average price of the share during the period February 24 - March 10, 2025.If all warrants of series TO 6 are exercised for the subscription of new shares, Dicot Pharma will receive

    Professor after ESSM: "The interest in Dicot Pharma's work continues to grow"

    Uppsala, Sweden, February 26, 2025. Dicot Pharma's potency drug candidate attracted a lot of attention during this weekend's edition of Europe's largest conference in sexual medicine.The pharmaceutical company Dicot Pharma was invited to present its clinical studies at ESSM, the leading European conference in sexual medicine, organized by the European Society for Sexual Medicine. The recurring conference, which this year took place on February 20-22 in Vienna, brings together the foremost experts in the field and serves as a central platform for the latest research findings and innovations.

    Dicot Pharma AB Year-End Report 2024

    Uppsala, Sweden, February 13, 2024. Dicot Pharma publishes its year-end report for the financial year 2024 and for the fourth quarter. The report is available as an attached document and on www.dicotpharma.com. CEO Elin Trampe and CFO Björn Petersson will present the report in a webcast today at 10.00 CET, which can also be viewed afterwards - see link below.Fourth quarter, October-December 2024  · Net sales amounts to SEK 0.0 million (0.0) · Earnings after financial items amounts to SEK -20.8 million (-15.7) · Earnings per share amounts to SEK -0.01 (-0.02) · Cash at end of

    Half of the participants now dosed in Dicot Pharma's Phase 2a study

    Uppsala, Sweden, February 5, 2025. The recruitment rate in the potency drug developer Dicot Pharma’s ongoing phase 2a study is high and in alignment with the planned timeline, where the study is expected to be reported in mid-2025. Today, half of the 140 participants have been dosed.Today, Dicot Pharma announces that the recruitment of participants for the company’s clinical phase 2a study is advancing at a steady rate, and that half of the planned 140 participants have now been dosed. “We set an ambitious recruitment plan, and thanks to the efficient work of our clinical partners and

    Entire Patent Family Reaching Approval in the United States

    Uppsala, Sweden, December 19, 2024. The pharmaceutical company Dicot Pharma today announces that the United States Patent and Trademark Office (USPTO) has granted an additional patent for its erectile dysfunction drug candidate, LIB-01. The patent is part of a patent family now gaining full approval in the US with protection until 2042. This family is paramount in the company´s IP-work and significantly strengthens both product and method protection.Dicot Pharma previously announced that the USPTO had issued a Notice of Allowance for three US patent applications within the same family. Two

    French Expert to Present Results from Dicot Pharma at ESSM

    Uppsala, Sweden, December 17, 2024. Results from Dicot Pharma's recent clinical trial have been selected for presentation at the European Society for Sexual Medicine’s annual congress. Professor François Giuliano, a urologist and specialist in male sexual health, will deliver a podium presentation on the findings from the company’s phase 1 clinical study as well as the study design for its ongoing phase 2a study, in which he serves as a medical expert.The European Society for Sexual Medicine (ESSM) is Europe's leading scientific organization in sexual medicine. Its annual conference gathers

    Dicot Pharma granted new patent in the USA

    Uppsala, Sweden, November 26, 2024. Dicot Pharma announces today that the US Patent and Trademark Office has granted a new patent covering important steps in the manufacturing of the potency drug candidate LIB-01.Dicot Pharma has received a new patent approved in the US that protects key steps in the manufacture of LIB-01 and is valid until 2042. Dicot Pharma has previously received a  Notice of Allowance for a total of three patent applications in the US, and this is the first of these to be formally approved. "It is of course a great success that we now obtain this important patent

    First participants dosed in Dicot Pharma's Phase 2a clinical study

    Uppsala, Sweden, November 20, 2024. The first participants in Dicot Pharma's Phase 2a clinical study have now been dosed. The company's drug candidate LIB-01 is being developed as a new first-line treatment for erectile dysfunction.Dicot Pharma has recently started its Phase 2a clinical study with the potency drug candidate LIB-01. The purpose of the study is to evaluate the efficacy of LIB-01 in men with erectile dysfunction. The first participants in the study have now been dosed, at sites in Stockholm and Gothenburg. All participants will be dosed for three consecutive days and then

    International business development expert joins Dicot Pharma

    Uppsala, Sweden, November 19, 2024. The potency drug developer Dicot Pharma, which recently initiated a phase 2a clinical trial and was listed on Nasdaq First North, is intensifying its focus on future commercialization. One measure is strengthening the management team with the appointment of a Chief Business Officer.The international business development expert Håkan Wickholm has been recruited for the CBO role. He brings extensive global experience from business development and multi-commercial roles within AstraZeneca such as Regional Business Development Director for Europe, the Middle

    Dicot Pharma announces initiation of Phase 2a clinical study

    Uppsala, Sweden, November 8, 2024. After recently receiving approval from authorities, the potency drug developer Dicot Pharma's clinical phase 2a study has now started. The primary objective of the study is to evaluate the efficacy of LIB-01 in patients with erectile dysfunction.Recruitment for the phase 2a study began immediately after the authority's approval and is managed by the company's clinical partner CTC, which is conducting the study.  Now the company announces that the study has formally started as the first screening visit has taken place. The primary objective of the phase

    Dicot Pharma listed on Nasdaq First North

    After six years on Spotlight Stock Market, the pharmaceutical company Dicot Pharma is moving to Nasdaq First North. The first day of trading is tomorrow after a live streamed bell ringing ceremony at Nasdaq.Since Dicot Pharma's share was listed on Spotlight in 2018, the number of shareholders has increased from 7 to approximately 7,250. The company believes that the change of listing to Nasdaq First North, which will take place on November 7, will benefit Dicot Pharma's continued development, internationalization and competitiveness. It is also expected to strengthen awareness of the

    Dicot Pharma presents interim report Q3 2024

    Uppsala, Sweden, October 31, 2024. Dicot Pharma AB publishes its interim report for the third quarter 2024. The report is available as an attached document and on the company's website www.dicotpharma.com.Third quarter, July-September 2024 · Net sales amounts to SEK 0.0 (0.0) million · Earnings after financial items amounts to SEK -10.2 (-8.5) million · Earnings per share amounts to SEK -0.01 (-0.01) “We are encouraged by the increasing interest in our company and drug development with each new milestone passed. The most recent example is the attention we garnered at SMSNA,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe